XSHE
002907
Market cap905mUSD
Oct 09, Last price
15.44CNY
1D
6.41%
1Q
8.89%
IPO
115.34%
Name
Chongqing Pharscin Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Chongqing Pharscin Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company actively involved in the research, development, manufacturing, and distribution of medicines. Its product portfolio encompasses a broad spectrum of pharmaceutical formulations, such as tablets, powders, granules, hard and soft capsules, alongside various injectables including powder, freeze-dried powder, and small volume injections. The company also specializes in active pharmaceutical ingredient (API) synthesis. This diverse range of products targets critical therapeutic areas, including the central nervous system (CNS), digestive health, otolaryngology, oncology, as well as cardiovascular and cerebrovascular conditions. Established in 1996, the company maintains its headquarters in Chongqing, China.
Key people
Xiaoyan Peng
Chief Financial Officer · since 2016
Hongtao You
Chairman of the Board, General Manager · since 2025
Jie Huang
Deputy General Manager · since 2024
Ying Wang
Deputy General Manager · since 2025
Yan Liang
Director · since 2016
Hao Shen
Director · since 2025
Kaiyu Xu
Staff Elected Director · since 2025
Xuedan You
Deputy General Manager, Secretary of the Board, Director · since 2022
Yuanyi You
Director · since 2019
Independent Director · since 2021
Hui Li
Independent Director · since 2021
Independent Director · since 2022
Shaorong Qin
Independent Director · since 2023
Independent Director · since 2016
Headquarters & legal address
重庆市荣昌区工业园区
万州区, CQ 400000
CN
万州区, CQ 400000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||